LG 100268 (Synonyms: AGN 192620, CD3127) |
| Catalog No.GC44059 |
LG 100268 (LG268) est un agoniste puissant, sélectif et actif par voie orale du récepteur X des rétinoïdes (RXR) avec des valeurs EC50 de 4 nM, 3 nM et 4 nM pour RXR-α, RXR-β et RXR-γ, respectivement.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 153559-76-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
LG 100268 is an agonist of retinoid X receptors (RXRs; Kd = 3 nM). It is selective for RXRs over retinoic acid receptors (RARs; Kd = >10,000 nM). In vitro, LG 100268 (1 µM) induces apoptosis in HL-60 human leukemia cells when used in combination with TTNPB . LG 100268 (100, 300, and 1,000 nM) dose-dependently inhibits COX-2 expression and increases ATP-binding cassette transporter (ABCA1) levels in macrophage-like RAW 264.7 cells. In vivo, it inhibits vinyl carbamate-induced lung tumor growth in mice when administered at a dose of 40 mg/kg.
Average Rating: 5 (Based on Reviews and 9 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *